These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 8853464

  • 1. Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity.
    Patel VF, Hardin JN, Mastro JM, Law KL, Zimmermann JL, Ehlhardt WJ, Woodland JM, Starling JJ.
    Bioconjug Chem; 1996; 7(4):497-510. PubMed ID: 8853464
    [Abstract] [Full Text] [Related]

  • 2. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
    Safavy A, Georg GI, Vander Velde D, Raisch KP, Safavy K, Carpenter M, Wang W, Bonner JA, Khazaeli MB, Buchsbaum DJ.
    Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
    [Abstract] [Full Text] [Related]

  • 3. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I.
    Cancer Res; 1997 Jan 01; 57(1):100-5. PubMed ID: 8988048
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
    Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA.
    Clin Cancer Res; 2004 Oct 15; 10(20):7063-70. PubMed ID: 15501986
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule].
    Liu XY, Zhen YS.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec 15; 23(6):563-7. PubMed ID: 12901099
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 15; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
    Narla RK, Chen CL, Dong Y, Uckun FM.
    Clin Cancer Res; 2001 Jul 15; 7(7):2124-33. PubMed ID: 11448932
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD.
    Bioconjug Chem; 2006 Jul 15; 17(1):114-24. PubMed ID: 16417259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.